AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29946756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 28318098 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 18
Study 28318098 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 18
Study 28318098 — intervention group
Group type: EXPERIMENTAL
Intervention: High BAT group (n = 6)
Number of subjects: 18
Study 28318098 — intervention group
Group type: EXPERIMENTAL
Intervention: Low BAT group (n = 12)
Number of subjects: 18
Study 24829053 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (ISB) - 10 ml mepivacaine 1 % and 20 ml ropivacaine 0.375%
Number of subjects: 120
Study 24829053 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA) - propofol, sunfentanil, desflurane
Number of subjects: 120
Study 24829053 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia + Interscalene brachial plexus block (GA + ISB)
Number of subjects: 120
Study 24829053 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (ISB)
Number of subjects: 120
Study 22999817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Outpatient (IOP)
Number of subjects: 300
Study 22999817 — intervention group
Group type: COMPARATOR
Intervention: Standard Outpatient (OP)
Number of subjects: 300
Study 21303402 — intervention group
Group type: COMPARATOR
Intervention: M‐MIST (control group)
Number of subjects: 45
Study 21303402 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐MIST + EMD
Number of subjects: 45
Study 21303402 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐MIST + EMD + BMDX
Number of subjects: 45
Study 19800722 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD)
Number of subjects: 423
Study 19800722 — intervention group
Group type: COMPARATOR
Intervention: Moderate-protein diet (MPD)
Number of subjects: 423
Study 16730604 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio Computer-Assisted Self Interview (ACASI)
Number of subjects: 2394
Study 16730604 — intervention group
Group type: COMPARATOR
Intervention: Self-Administered (SA)
Number of subjects: 2394
Study 16730604 — intervention group
Group type: COMPARATOR
Intervention: Interviewer-Administered (IA)
Number of subjects: 2394
Study 16730604 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-Pencil Self-Administered (SA)
Number of subjects: 2394
Study 12738464 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 1 mg/kg
Number of subjects: 21
Study 12738464 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 21
Study 12738464 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg
Number of subjects: 21
Study 10874600 — intervention group
Group type: EXPERIMENTAL
Intervention: AAACa (900 mg/day elemental calcium)
Number of subjects: 4
Study 10874600 — intervention group
Group type: COMPARATOR
Intervention: AACa (900 mg/day elemental calcium)
Number of subjects: 4
Study 10874600 — intervention group
Group type: COMPARATOR
Intervention: CaCO3 (900 mg/day elemental calcium)
Number of subjects: 4
Study 10874600 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no elemental calcium)
Number of subjects: 4
Study 9059470 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 40 ppm for 20 minutes
Number of subjects: 34
Study 9059470 — intervention group
Group type: COMPARATOR
Intervention: Air (control) inhaled for 20 minutes
Number of subjects: 34
Study 3490970 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 3490970 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 30
Study 31301173 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional inference approach for obtaining confidence intervals for eQTL effect sizes
Number of subjects: 0
Study 31301173 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of GTEx Liver dataset (v6)
Number of subjects: 0
Study 29568771 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures
Number of subjects: 102
Study 29568771 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-triclosan sutures)
Number of subjects: 102
Study 25844507 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonextraction (Class I malocclusion)
Number of subjects: 103
Study 25844507 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonextraction (Class II malocclusion)
Number of subjects: 103
Study 25844507 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction (Class I malocclusion)
Number of subjects: 103
Study 25844507 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction (Class II malocclusion)
Number of subjects: 103
Study 24424780 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 25935 (12 mg)
Number of subjects: 32
Study 24424780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 22442168 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of silent infarcts (SIs)
Number of subjects: 395
Study 22442168 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of microbleeds (MBs)
Number of subjects: 395
Study 22442168 — intervention group
Group type: COMPARATOR
Intervention: No silent infarcts or microbleeds (control group)
Number of subjects: 395
Study 20001536 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 90
Study 20001536 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (control)
Number of subjects: 90
Study 18706998 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide with ketoconazole (16mg) in jejunum
Number of subjects: 8
Study 18706998 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide with ketoconazole (16mg) in ileum
Number of subjects: 8
Study 18706998 — intervention group
Group type: COMPARATOR
Intervention: Budesonide in colon
Number of subjects: 8
Study 18706998 — intervention group
Group type: COMPARATOR
Intervention: Intravenously administered budesonide
Number of subjects: 8
Study 16887334 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 263
Study 16887334 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 263
Study 12791114 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 35
Study 12791114 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 35
Study 11039260 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate 2,500 mg/day (1,000 mg of calcium)
Number of subjects: 28
Study 11039260 — intervention group
Group type: COMPARATOR
Intervention: Calcium acetate 1,000 mg (254 mg of calcium)
Number of subjects: 28
Study 9001380 — intervention group
Group type: EXPERIMENTAL
Intervention: d2‐PteGlu6 blended into orange juice
Number of subjects: 7
Study 9001380 — intervention group
Group type: EXPERIMENTAL
Intervention: d2‐PteGlu6 blended into tomatoes
Number of subjects: 7
Study 9001380 — intervention group
Group type: EXPERIMENTAL
Intervention: d2‐PteGlu6 blended into lima beans
Number of subjects: 7
Study 9001380 — intervention group
Group type: EXPERIMENTAL
Intervention: d2‐PteGlu6 blended into citrate buffer
Number of subjects: 7
Study 9001380 — intervention group
Group type: COMPARATOR
Intervention: d2‐PteGlu6 blended into water (control)
Number of subjects: 7
Study 1623349 — intervention group
Group type: EXPERIMENTAL
Intervention: Resurfacing
Number of subjects: 3
Study 1623349 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dermabrasion
Number of subjects: 3
Study 1623349 — intervention group
Group type: COMPARATOR
Intervention: Dermabrasion
Number of subjects: 3
Study 6394349 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide 6 mg b.d.
Number of subjects: 110
Study 6394349 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide 6 mg + Triamterene 50 mg b.d.
Number of subjects: 110
Study 6394349 — intervention group
Group type: COMPARATOR
Intervention: Triamterene 50 mg b.d.
Number of subjects: 110
Study 30053728 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐alanine supplementation for 28 days
Number of subjects: 14
Study 30053728 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise CAR‐ACR content after β‐alanine supplementation
Number of subjects: 14
Study 30053728 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 14
Study 30053728 — intervention group
Group type: COMPARATOR
Intervention: Supplementation alone
Number of subjects: 14
Study 26459780 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 64
Study 26459780 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil (100 mg)
Number of subjects: 64
Study 23506257 — intervention group
Group type: EXPERIMENTAL
Intervention: Human breast milk
Number of subjects: 63
Study 23506257 — intervention group
Group type: COMPARATOR
Intervention: Barrier cream (40% zinc oxide with cod liver oil formulation)
Number of subjects: 63
Study 23776431 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-vitamin B-6 diet (<0.5 mg/d)
Number of subjects: 23
Study 20805344 — intervention group
Group type: EXPERIMENTAL
Intervention: Early class III protraction facemask treatment (PFG)
Number of subjects: 73
Study 20805344 — intervention group
Group type: COMPARATOR
Intervention: Control/no treatment (CG)
Number of subjects: 73
Study 18768335 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate
Number of subjects: 1583
Study 18768335 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of glucosamine and chondroitin sulfate
Number of subjects: 1583
Study 18768335 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 1583
Study 18768335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1583
Study 15940172 — intervention group
Group type: EXPERIMENTAL
Intervention: Entero-sorption with pectin-containing medication
Number of subjects: 150
Study 15940172 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control group)
Number of subjects: 150
Study 12463728 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat meal (two slices of bread and 200 ml of apple juice)
Number of subjects: 9
Study 12463728 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (two slices of bread with 30 gm of butter and 200 ml of apple juice)
Number of subjects: 9
Study 12463728 — intervention group
Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 9
Study 10328649 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerative therapy using bioactive glass
Number of subjects: 15
Study 10328649 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement alone
Number of subjects: 15
Study 7574019 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 81
Study 7574019 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 81
Study 1754868 — intervention group
Group type: EXPERIMENTAL
Intervention: IS-5-MN 20 mg b.i.d. or t.i.d.
Number of subjects: 251
Study 1754868 — intervention group
Group type: EXPERIMENTAL
Intervention: s.r. nifedipine 20 mg b.i.d. or 40 mg b.i.d.
Number of subjects: 251
Study 1754868 — intervention group
Group type: COMPARATOR
Intervention: IS-5-MN and s.r. nifedipine
Number of subjects: 251
Study 7127996 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (200 to 300 mg b.i.d.)
Number of subjects: 9
Study 31405823 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational physical activity program (G1)
Number of subjects: 123
Study 31405823 — intervention group
Group type: COMPARATOR
Intervention: As usual care control group (G2)
Number of subjects: 123
Study 31551206 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg orally once daily for the first 21 days of each 28‐day cycle plus Best Supportive Care (BSC)
Number of subjects: 0
Study 31551206 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed 500 mg/m2 intravenously on Day 1 of each 21‐day cycle plus cisplatin 75 mg/m2 i.v. beginning 30 minutes after pemetrexed administration plus Best Supportive Care (BSC)
Number of subjects: 0
Study 31551206 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regorafenib and pemetrexed
Number of subjects: 0
Study 29149904 — intervention group
Group type: COMPARATOR
Intervention: 7-day standard triple therapy (lansoprazole, amoxicillin, and clarithromycin)
Number of subjects: 0
Study 29149904 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (lansoprazole and amoxicillin for the first 5 days, followed by lansoprazole, clarithromycin, and metronidazole for another 5 days)
Number of subjects: 0
Study 29149904 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day concomitant therapy (lansoprazole, amoxicillin, clarithromycin, and metronidazole)
Number of subjects: 0
Study 26335108 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive videogame therapy (VGT)
Number of subjects: 17
Study 26335108 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy ROM activities (ST)
Number of subjects: 17
Study 24744200 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic 320-row multi-detector computed tomography (MDCT)
Number of subjects: 32
Study 24744200 — intervention group
Group type: COMPARATOR
Intervention: Positron-emission tomography (PET)
Number of subjects: 32
Study 22947344 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract
Number of subjects: 168
Study 22947344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 19237874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (insulin titrated to maintain blood glucose levels within the range of 4.44‐6.11 mM)
Number of subjects: 483
Study 17389707 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) and isoprenaline
Number of subjects: 24
Study 17389707 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone-sensitive lipase gene expression
Number of subjects: 24
Study 17389707 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression of UCP2
Number of subjects: 24
Study 17389707 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression of PDE3B
Number of subjects: 24
Study 17389707 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression of other genes
Number of subjects: 24
Study 15466769 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimethod quality improvement intervention
Number of subjects: 87291
Study 15466769 — intervention group
Group type: COMPARATOR
Intervention: Less intensive intervention (Control)
Number of subjects: 87291
Study 11812331 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound with Jieeryin as irrigant (experimental group)
Number of subjects: 60
Study 11812331 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound with saline as irrigant (control group 2)
Number of subjects: 60
Study 11812331 — intervention group
Group type: COMPARATOR
Intervention: Hand instruments (control group 1)
Number of subjects: 60
Study 11097449 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine alone
Number of subjects: 55
Study 11097449 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with betamethasone
Number of subjects: 55
Study 11097449 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 55
Study 9075340 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 0
Study 9075340 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AM)
Number of subjects: 0
Study 9075340 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9075340 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) and Amodiaquine (AM)
Number of subjects: 0
Study 8154130 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-induced extracorporeal LDL precipitation (HELP)
Number of subjects: 0
Study 3816921 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release diltiazem (120 mg)
Number of subjects: 12
Study 3816921 — intervention group
Group type: COMPARATOR
Intervention: Conventional diltiazem tablet (120 mg)
Number of subjects: 12
Study 30488789 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (low-molecular-weight heparin)
Number of subjects: 37
Study 30488789 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (direct oral anticoagulant)
Number of subjects: 37
Study 30488789 — intervention group
Group type: EXPERIMENTAL
Intervention: General experience of anticoagulation
Number of subjects: 37
Study 30488789 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of thrombosis risk
Number of subjects: 37
Study 28750840 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 128
Study 28750840 — intervention group
Group type: COMPARATOR
Intervention: Sham-electroacupuncture (SA)
Number of subjects: 128
Study 27200393 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-plasty reconstruction
Number of subjects: 52
Study 27200393 — intervention group
Group type: COMPARATOR
Intervention: Traditional median neurolysis
Number of subjects: 52
Study 24397361 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone capsules 200 mg once daily from the day after insemination until next menstruation or continuing for up to 8 weeks of pregnancy.
Number of subjects: 398
Study 24397361 — intervention group
Group type: COMPARATOR
Intervention: No luteal phase support (control group).
Number of subjects: 398
Study 22330964 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 759
Study 22330964 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 759
Study 22330964 — intervention group
Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 759
Study 22330964 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 759
Study 20127893 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing acoustic cardiography
Number of subjects: 90
Study 20127893 — intervention group
Group type: COMPARATOR
Intervention: Auscultation alone
Number of subjects: 90
Study 18336723 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular cleaning products containing hypochlorite
Number of subjects: 3
Study 18336723 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular products plus three additional products with dilute hypochlorite
Number of subjects: 3
Study 18336723 — intervention group
Group type: COMPARATOR
Intervention: Control group (no products)
Number of subjects: 3
Study 18336723 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic product groups (hypochlorite-based cleaning supplies)
Number of subjects: 3
Study 15372158 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial electromyography (EMG) measuring joy-relevant facial muscles (zygomaticus major, orbicularis oculi, levator labii superioris)
Number of subjects: 40
Study 15372158 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial electromyography (EMG) measuring nonjoy-relevant facial muscles (frontalis, corrugator supercilii)
Number of subjects: 40
Study 15372158 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 40
Study 12190757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure
Number of subjects: 50
Study 12190757 — intervention group
Group type: COMPARATOR
Intervention: Sham pressure (Control)
Number of subjects: 50
Study 9880379 — intervention group
Group type: COMPARATOR
Intervention: Vigorous exercise <1 time per week
Number of subjects: 21823
Study 9880379 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise 1 time per week
Number of subjects: 21823
Study 9880379 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise 2 to 4 times per week
Number of subjects: 21823
Study 9880379 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise ≥5 times per week
Number of subjects: 21823
Study 9880379 — intervention group
Group type: COMPARATOR
Intervention: Vigorous exercise <1 time per week (after additional adjustments)
Number of subjects: 21823
Study 9880379 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise 1 time per week (after additional adjustments)
Number of subjects: 21823
Study 9880379 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise 2 to 4 times per week (after additional adjustments)
Number of subjects: 21823
Study 9880379 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise ≥5 times per week (after additional adjustments)
Number of subjects: 21823
Study 7493433 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (1000 i.u. per day for 4 weeks)
Number of subjects: 17
Study 7493433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 1771216 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg dexamethasone phosphate
Number of subjects: 12
Study 1771216 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone phosphate
Number of subjects: 12
Study 1771216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31977634 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination within 2 h after the last training session
Number of subjects: 45
Study 31977634 — intervention group
Group type: COMPARATOR
Intervention: Vaccination after 24‐26 h
Number of subjects: 45
Study 31977634 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisbane strain neutralization titers
Number of subjects: 45
Study 31977634 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 45
Study 28855077 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 10061
Study 28855077 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 300 mg
Number of subjects: 10061
Study 28855077 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab pooled
Number of subjects: 10061
Study 28855077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10061
Study 26159458 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 54
Study 26159458 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 54
Study 26159458 — intervention group
Group type: COMPARATOR
Intervention: Dasatinib or Nilotinib
Number of subjects: 54
Study 24334945 — intervention group
Group type: EXPERIMENTAL
Intervention: Coartem (artemether-lumefantrine)
Number of subjects: 182